EANO Meeting - Saturday, September 23, 2023
Note that the programme is subject to change and will be continuously updated.
All times below refer to Central European Summer Time (CEST).
08:00-09:00 hrs
Chairs: tba
ME04.1 EANO-EURACAN-SNO guideline on circumscribed astrocytic, glioneuronal and neuronal tumors
Roberta Ruda, Italy
ME04.2 ESTRO-EANO guideline on delineation for glioblastoma for radiotherapy
Guiseppe Minniti, Italy
ME04.3 EANO guideline for diagnostics according to WHO 2021 brain tumor classification
Felix Sahm, Germany
ME04.4 EANO guideline on testing for targeted treatments: beyond the WHO 2021CNS tumors classification
Martin van den Bent, Netherlands
Chairs: tba
ME05.1 Radioligand therapy: a novel therapeutic strategy in glioblastoma?
Nathalie Lisa Albert, Germany
ME05.2 A Nanotechnology Toolkit for the Total Management of Glioblastoma
Kostas Kostarelos, United Kingdom
ME05.3 Novel technologies for liquid biopsy
Florent Mouliere, Netherlands
Chairs: tba
ME06.1 Surgical management
Marcos Tatagiba, Germany
ME06.2 Radiation therapy options
Bente Sandvei, Norway
ME06.3 Clinical management of NF2 patients
Oliver Hanemann, United Kingdom
ME06.4 MEK inhibition in the management of NF1-associated tumors
Walter Taal, Netherlands
09:00-09:15 hrs | BREAK
09:15-10:45 hrs
Chairs: tba
JS04.1 Impact of molecular classification of adult diffuse glioma on the role of surgery
Shawn Hervey-Jumper, United States
JS04.2 Implications of molecular drivers in tumor predisposition syndromes
Evangelia Razis, Greece
JS04.3 Review of the impact of molecular classification in the management of pediatric brain tumors
Richard Gilbertson, United Kingdom
JS04.4 Clinical trials in the molecular era
Isabel Arrillaga, United States
Chairs: tba
JS05.1 Heterogeneity in decision making and treatment selection for glioma patients
Arnaud Vincent, Netherlands
JS05.2 FLAIRectomy. A new paradigm in glioblastoma surgery
Giuseppe Barbagallo, Italy
JS05.3 Biopsy vs. resection in the elderly glioblastoma patient
Florence Laigle-Donadey, France
JS05.4 Biopsy vs. resection: The neuro-oncologist perspective
Marjolein Geurts, Netherlands
Chairs: tba
OS06.1 Current status of artificial intelligence and radiomics in neuro-oncology
Philipp Lohmann, Germany
OS06.2 Challenges and implications of artificial intelligence and radiomics in neuro-oncology
Pallavi Tiwari, United States
OS06.3 Status quo of artificial intelligence and radiomics in clinical routine
Mariam Aboian, United States
OS06.3 Advanced computational image analysis and modeling in neurooncology
Benedikt Wiestler, Germany
10:45-11:15 hrs | COFFEE BREAK
11:15-12:45 hrs
Chairs: tba
OS07.1 Mapping the rules of glioblastoma using single cell and spatial genomics
Omer Bayrakter, United Kingdom
OS07.2 Spatio-temporal remodeling of tumor architecture under therapy
Dieter Henrik Heiland, Germany
OS07.3 Tumor architecture of pediatric brain tumors
Mariella Filbin, United States
OS07.4 Single cell tumor atlas to understand tumor architecture (GBMap)
Henrik Stunnenberg, Netherlands
Chairs: tba
OS08.1 Quality of care at the End of Life in Brain Tumor patients
Andrea Pace, Italy
OS08.2 End-of-life care for glioma patients: the caregivers' perspective
Caroline Hertler, Switzerland
OS08.3 Advance care planning
Johan Koekkoek, Netherlands
OS08.4 Telehealth platforms for delivering supportive care to adults with primary brain tumors and their family caregivers
Tamara Ownsworth, Australia
12:45-14:15 hrs | LUNCH BREAK
13:00-14:00 hrs
Chairs: tba
WS02.1 Integrated diagnoses and layered reports
Niek Maas, Netherlands
WS02.2 Upcoming novel diagnoses in the 6th WHO-classification
Abigail Suwala, Germany
WS02.3 How to understand methylome-analysis
Leonille Schweizer, Germany
WS02.4 How do new techniques translate into clinical care?
Kathreena Kurian, United Kingdom
14:15-15:45 hrs
Chairs: tba
OS10.1 Co-option of neuronal programs in recurrent glioblastoma
Roel Verhaak, United States
OS10.2 Olfactory sensory experience regulates gliomagenesis via neuronal IGF1
Chong Liu, China
OS10.3 Neuronal progenitor mimicry of invasive glioma and therapeutic implications
Varun Venkataramani, Germany
OS10.4 Mechanisms of neuron-tumor crosstalk in pediatric brain tumors
Michelle Monje, United States
Chairs: tba
OS11.1 First-line glioblastoma treatment with TMZ plus CCNU - pro arguments
Johannes Weller, Germany
OS11.2 First-line glioblastoma treatment with TMZ plus CCNU - con arguments
Marjolein Geurts, Netherlands
OS11.3 MRI vs PET for detection of pseudoprogression - Advanced MRI
Mariam Aboian, United States
OS11.4 MRI vs PET for detection of pseudoprogression - PET
Norbert Galldiks, Germany
OS11.5 Treatment of recurrent glioma with regorafenib - pro arguments
Giuseppe Lombardi, Italy
OS11.6 Treatment of recurrent glioma with regorafenib - con arguments
Anna Berghoff, Austria
Chairs: tba
OS12.1 Multidisciplinary approach and new molecular advances
Alvaro Lasaletta, Spain
OS12.2 Fertility and pregnancy
Marie-Therese Forster, Germany
OS12.3 The journey of survivorship
Rachael Simms-Moore, United Kingdom
OS12.4 The daily life challenges of adolescents and adults with an uncertain or poor cancer prognosis
Olga Husson, Netherlands
15:45-16:00 hrs | BREAK
16:00-17:00 hrs
Chairs: tba
JS06.1 SRS vs WBRT for multiple brain metastases
Brigitta Baumert, Switzerland
JS06.2 Immunomodulation of RT: preclinical models and clinical translation
Claire Vanpouille-Box, United States
JS06.3 Pre- vs post-operative SRS for brain metastases
Anca Grosu, Germany
Chairs: tba
JS07.1 EURACAN updates
Enrico Franceschi, Italy
JS07.2 ePAG : the patient perspective e and role
Kathy Oliver, United Kingdom
JS07.3 Pineal tumors, update from the EURACAN guidelines group
Giuseppe Lombardi, Italy
